In B-cell lymphomas, an allogeneic CD19 CAR-NK product expressing membrane-bound IL-15 showed no dose-limiting toxicities and achieved an 80% overall response rate at the highest dose level (NCT05020678) (70). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.